Hot Features
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults wi... Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 6.4031 | 15.0519511048 | 42.54 | 48.9431 | 42.22 | 2113674 | 46.13379004 | CS |
| 4 | 6.2731 | 14.7014295758 | 42.67 | 48.9431 | 33.45 | 1941166 | 41.83448383 | CS |
| 12 | 9.7931 | 25.0143039591 | 39.15 | 48.9431 | 33.45 | 1213806 | 42.42092522 | CS |
| 26 | 32.2731 | 193.599880024 | 16.67 | 48.9431 | 14.785 | 1229551 | 34.77384202 | CS |
| 52 | 28.4831 | 139.213587488 | 20.46 | 48.9431 | 14.785 | 888277 | 30.01315127 | CS |
| 156 | 28.6231 | 140.861712598 | 20.32 | 48.9431 | 9.8 | 455886 | 26.73799212 | CS |
| 260 | 24.7431 | 102.244214876 | 24.2 | 48.9431 | 9.8 | 430981 | 26.46891763 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.